EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics
EYPT Price/Volume Stats
| Current price | $8.18 | 52-week high | $15.63 |
| Prev. close | $8.00 | 52-week low | $2.19 |
| Day low | $7.94 | Volume | 112,544 |
| Day high | $8.25 | Avg. volume | 616,129 |
| 50-day MA | $11.39 | Dividend yield | N/A |
| 200-day MA | $6.59 | Market Cap | 286.17M |
EYPT Stock Price Chart Interactive Chart >
EYPT POWR Grades
- Value is the dimension where EYPT ranks best; there it ranks ahead of 86.92% of US stocks.
- The strongest trend for EYPT is in Quality, which has been heading up over the past 177 days.
- EYPT ranks lowest in Stability; there it ranks in the 5th percentile.
EYPT Stock Summary
- For EYPT, its debt to operating expenses ratio is greater than that reported by just 9.04% of US equities we're observing.
- With a year-over-year growth in debt of -87.74%, EYEPOINT PHARMACEUTICALS INC's debt growth rate surpasses just 1.58% of about US stocks.
- In terms of volatility of its share price, EYPT is more volatile than 93.66% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to EYEPOINT PHARMACEUTICALS INC are ONTO, SMSI, KLIC, INSG, and ABSI.
- Visit EYPT's SEC page to see the company's official filings. To visit the company's web site, go to eyepointpharma.com.
EYPT Valuation Summary
- EYPT's EV/EBIT ratio is -1.6; this is 113.79% lower than that of the median Healthcare stock.
- EYPT's price/sales ratio has moved down 1296.1 over the prior 227 months.
Below are key valuation metrics over time for EYPT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EYPT | 2023-09-22 | 7.9 | 5.2 | -2.8 | -1.6 |
| EYPT | 2023-09-21 | 7.8 | 5.1 | -2.8 | -1.5 |
| EYPT | 2023-09-20 | 8.0 | 5.2 | -2.8 | -1.6 |
| EYPT | 2023-09-19 | 8.8 | 5.7 | -3.1 | -1.9 |
| EYPT | 2023-09-18 | 9.1 | 5.9 | -3.2 | -2.0 |
| EYPT | 2023-09-15 | 9.8 | 6.4 | -3.5 | -2.2 |
EYPT Growth Metrics
- The 3 year revenue growth rate now stands at 588.06%.
- Its 3 year net cashflow from operations growth rate is now at -31.32%.
- The 4 year cash and equivalents growth rate now stands at 103.13%.
The table below shows EYPT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 42.415 | -69.085 | -78.234 |
| 2022-06-30 | 41.462 | -63.736 | -76.509 |
| 2022-03-31 | 38.91 | -55.156 | -67.113 |
| 2021-12-31 | 36.939 | -50.097 | -58.417 |
| 2021-09-30 | 32.526 | -27.534 | -54.454 |
| 2021-06-30 | 39.162 | -18.611 | -41.56 |
EYPT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EYPT has a Quality Grade of C, ranking ahead of 30.89% of graded US stocks.
- EYPT's asset turnover comes in at 0.293 -- ranking 58th of 75 Measuring and Control Equipment stocks.
- BRKR, HURC, and ONTO are the stocks whose asset turnover ratios are most correlated with EYPT.
The table below shows EYPT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.293 | 0.804 | -0.673 |
| 2021-03-31 | 0.322 | 0.818 | -0.674 |
| 2020-12-31 | 0.433 | 0.831 | -0.636 |
| 2020-09-30 | 0.480 | 0.870 | -0.520 |
| 2020-06-30 | 0.301 | 0.862 | -0.717 |
| 2020-03-31 | 0.319 | 0.871 | -0.715 |
EYPT Price Target
For more insight on analysts targets of EYPT, see our EYPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $21.20 | Average Broker Recommendation | 1.4 (Strong Buy) |
EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio
EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.
Latest EYPT News From Around the Web
Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an ag |
Why Shares of EyePoint Pharmaceuticals Were Rising MondayThe company reported positive trial data for its lead therapy to treat two different eye conditions. |
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesWATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the Company will participate at the following upcoming conferences: Citi's 18th Annual BioPharma ConferenceForum: 1x1 Investor MeetingsDate: Wednesday, September 6, 2023 H.C. Wainwright 25th Annual Global Investment ConferenceForum: Corp |
EyePoint Pharmaceuticals: A Significantly Overvalued Stock?An in-depth analysis of EyePoint Pharmaceuticals' intrinsic value and financial performance |
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceWATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Jay S. Duker, M.D., President and Chief Executive of EyePoint Pharmaceuticals will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference: Company OverviewDate: Wednesday, August 16th, 2023Time: Available on-demand at 7:00 a.m. ET S |
EYPT Price Returns
| 1-mo | -29.79% |
| 3-mo | -0.49% |
| 6-mo | 178.23% |
| 1-year | 16.86% |
| 3-year | 45.11% |
| 5-year | -77.09% |
| YTD | 133.71% |
| 2022 | -71.41% |
| 2021 | 86.02% |
| 2020 | -57.55% |
| 2019 | -17.99% |
| 2018 | 75.00% |
Continue Researching EYPT
Here are a few links from around the web to help you further your research on EyePoint Pharmaceuticals Inc's stock as an investment opportunity:EyePoint Pharmaceuticals Inc (EYPT) Stock Price | Nasdaq
EyePoint Pharmaceuticals Inc (EYPT) Stock Quote, History and News - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...